The funds described herein are open to “accredited investors” only, through an offering made in accordance with Regulation D, Rule 506(c) of the Securities Act of 1933, as amended. In purchasing securities through a 506(c) offering, we are obligated to verify any participating investor’s status as an “accredited investor” in accordance with Rule 501 of Regulation D. Investors should consider the investment objectives, risks, charges, and expenses of the fund carefully before investing. We do not make any representations as to the accuracy or completeness of the information contained on this website and undertake no obligation to update the information. Past performance is not an indicator of any future results. All investments contain risk and may lose value. This does not constitute an offer to sell or a solicitation of interest to purchase any securities or investment advisory services in any country or jurisdiction in which such offer or solicitation is not permitted by law.

David Karli, the Medical Entrepreneur

In this Show

Greyledge CEO Dave Karli MD, biotech startup & optimizing the process of regenerative medicine.

What is Greyledge Technology?

-A biotech company that works with the patient’s own tissue samples. We’ll take a tissue from you, typically blood or bone marrow tissue, and we manipulate that into a sample in a therapeutic that’s placed back either via injection, or as part of the surgical technique where our surgeon implants it.

Get in contact with David C. Karli through his website, LinkedIn, and learn more about Greyledge Technologies here:

davidkarli.com

https://www.linkedin.com/in/davidkarli/

https://www.greyledgebiotech.com/

(Visited 45 times, 1 visits today)